DCC2630 |
Iap-in-1 |
Novel antagonist of IAP (inhibitor of apoptosis protein) |
|
DCC2631 |
Iaxo-101 |
Novel inhibitor of the cluster of differentiation 14 innate immunity pathway |
|
DCC2632 |
Ibe-667 |
Novel activator of LFA-1-ICAM-1 binding |
|
DCC2633 |
Ibl-302 |
First-in-class triple-acting PIM/PI3K/mTOR inhibitor, demonstrating single-agent, anti-tumour efficacy in suppression of pAKT, pmTOR and pBAD in the SKBR-3, BT-474 and HCC-1954 HER2+/PIK3CA-mutated cell lines |
|
DCC2634 |
Ibpr001 Hydrochloride |
Novel Aurora kinase inhibitor |
|
DCC2635 |
Ibpr002 |
Novel Aurora kinase inhibitor, revealing mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules |
|
DCC2636 |
Ibrutinib-bfl |
Novel fluorescent irreversible inhibitor of Bruton's tyrosine kinase (BTK) |
|
DCC2637 |
Ibs399024 |
Novel HDAC6-selective inhibitor |
|
DCC2638 |
Ic2418 |
MmpL3 inhibitor, being active against drug-resistant Mycobacterium tuberculosis |
|
DCC2639 |
ica-27243 |
Neuronal Kv7 potassium channel activator |
|
DCC2640 |
Icagen-4 |
Inhibitor of voltage-gated K(+) (Kv) channels Kv1.3 and Kv1.5 |
|
DCC2641 |
Ical-36 |
Novel inhibitor of CALP, exhibiting affinity of 22.6 ± 8.0 μM for CALP and no interaction with the NHERF PDZ domains |
|
DCC2642 |
icec0943 |
Novel selective inhibitor of CDK7 |
|
DCC2643 |
Ici-185282 |
Potent thromboxane receptor antagonist |
|
DCC2644 |
Ici-56780 |
Antimalarial agent, displaying blood schizonticidal activity against P.berghei |
|
DCC2645 |
Iclaprim |
Novel selective bacterial dihydrofolate inhibitor, antibiotic, actively against Gram positive organisms |
|
DCC2646 |
Icl-ccic-0019 |
Novel potent and selective inhibitor of choline kinase alpha (CHKA) |
|
DCC2647 |
Icl-sirt078 |
Novel highly selective, substrate-competitive SIRT2 inhibitor, displaying a significant neuroprotective effect in a lactacystin-induced model of Parkinsonian neuronal cell death in the N27 cell line |
|
DCC2648 |
Icpd62 |
Novel inhibitor of heat shock protein 90 (Hsp90), demonstrating anticancer activity against colorectal, osteosarcoma and cervical cancer cell lines |
|
DCC2649 |
Icrf-193 |
DNA topoisomerase II inhibitor |
|
DCC2650 |
Ict2700 |
Potent cytotoxin selectively by CYP1A1 as a tumor-selective treatment for human bladder cancers |
|
DCC2651 |
Id110460001 |
Novel μ,δ-Opioid Receptor Dual-Biased Agonist, Overcoming the Limitation of Prior Biased Agonist |
|
DCC2652 |
Id110460002 |
Novel μ,δ-Opioid Receptor Dual-Biased Agonist, Overcoming the Limitation of Prior Biased Agonist |
|
DCC2653 |
Id110460003 |
Novel μ,δ-Opioid Receptor Dual-Biased Agonist, Overcoming the Limitation of Prior Biased Agonist |
|
DCC2654 |
idaverine |
M1 and M2 Antagonist |
|
DCC2655 |
Ide-in-37 Tfa Salt |
Novel highly potent substrate-selective inhibitor of insulin-degrading enzyme (IDE), blocking insulin binding while allowing glucagon cleavage, even at saturating inhibitor concentrations |
|
DCC2656 |
Ide-in-63 Tfa Salt |
Novel highly potent substrate-selective inhibitor of insulin-degrading enzyme (IDE), blocking insulin binding while allowing glucagon cleavage, even at saturating inhibitor concentrations |
|
DCC2657 |
Idh2 Inhibitor |
Novel isocitrate dehydrogenase 2 (IDH2) mutants inhibitor for the treatment of cancer |
|
DCC2658 |
Idi-3783 |
Novel mutant-selective Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor |
|
DCC2659 |
Ido1/2 Inhibitor 4t |
The first inhibitor targeting both IDO1/2 that has excellent in vitro inhibitory activity (IDO1 IC50 = 28 nM and IDO2 IC50 = 144 nM) |
|